Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems


FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

Approved for prostate cancer patients previously treated with docetaxel, another anti-cancer treatment, Xtandi was reviewed under the FDA’s priority review program.… FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer   

zytiga5 - american journal of clinical nutrition1 - ckd progression1 - urinary excretion1 - cadmium toxicity1 - poststreptococcal glomerulonephritis2 - chromosome defects1 - acidosis1 - medullary cystic disease1 - av fistula1 - urethral pressure measurement3 - urinary tract disorder1 - sexually transmitted disease1 - imrt2 - genetic disease1 - zygote intrafallopian transfer1 - differential diagnosis1 - plos one1 - robotic-assisted radical prostatectomy1 - cihi1 - acute renal failure1 - overhydration1 - uterine cancer4 - femoral artery1 - salt1 - ultrasonography1 - matrix calculus3 - sexual intercourse4 - prostate cancer mortality1 - sarcoidosis1 -